Naveen Pemmaraju: The largest annual meeting in all of hematology blood disorders – ASH24
Naveen Pemmaraju, Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a post on LinkedIn:
“I recently returned from the largest annual meeting in all of hematology blood disorders – ASH24.
I was honored to moderate an ASH Education session and speak on BPDCN at the ASH24 American Society of Hematology annual meeting.
Our well-attended session was entitled Chasing Zebras – Navigating Rare Myeloid Neoplasms.
We focused on several topics of interest including CSF3R-driven malignancies, acute leukemias of ambiguous lineage and BPDCN.
I was delighted to be joined by my co-panellists Dr. Olga Weinberg, MD and Dr. Robert Hasserjian to all for the continued support as we, together, grow the Rare Disease community.”
More posts featuring Naveen Pemmaraju.
Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.
His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023